Kairos Capital Management SC 13G/A Arbutus Biopharma / Two Seas Capital ownership change

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________

Schedule 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. 2)*

_____________________________________

Arbutus Biopharma Corporation

(Name of Issuer)

Common Shares, without par value

(Title of Class of Securities)

03879J100

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 03879J100


(1)	Name of Reporting Persons: Two Seas Capital LP
(2)	Check the Appropriate Box if a Member of a Group (See Instructions): (a) ☐ (b) ☐
(3)	SEC Use Only:
(4)	Citizenship or Place of Organization: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		(5)	Sole Voting Power 8,387,388
		(6)	Shared Voting Power 0
		(7)	Sole Dispositive Power 8,387,388
		(8)	Shared Dispositive Power 0
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person: 8,387,388
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): ☐
(11)	Percent of Class Represented by Amount in Row (9): 4.4%*
(12)	Type of Reporting Person (See Instructions): IA, PN

*	Based on 189,438,135 Common Shares, without par value (“Common Shares”), of Arbutus Biopharma Corporation (the “Issuer”) outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 6, 2024.

CUSIP No. 03879J100


(1)	Name of Reporting Persons: Two Seas Capital GP LLC
(2)	Check the Appropriate Box if a Member of a Group (See Instructions): (a) ☐ (b) ☐
(3)	SEC Use Only:
(4)	Citizenship or Place of Organization: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		(5)	Sole Voting Power 8,387,388
		(6)	Shared Voting Power 0
		(7)	Sole Dispositive Power 8,387,388
		(8)	Shared Dispositive Power 0
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person: 8,387,388
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): ☐
(11)	Percent of Class Represented by Amount in Row (9): 4.4%*
(12)	Type of Reporting Person (See Instructions): OO, HC

*	Based on 189,438,135 Common Shares of the Issuer outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024.

CUSIP No. 03879J100


(1)	Name of Reporting Persons: Sina Toussi
(2)	Check the Appropriate Box if a Member of a Group (See Instructions): (a) ☐ (b) ☐
(3)	SEC Use Only:
(4)	Source of Funds (See Instructions): United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		(5)	Sole Voting Power 8,387,388
		(6)	Shared Voting Power 0
		(7)	Sole Dispositive Power 8,387,388
		(8)	Shared Dispositive Power 0
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person: 8,387,388
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): ☐
(11)	Percent of Class Represented by Amount in Row (9): 4.4%*
(12)	Type of Reporting Person (See Instructions): IN, HC

*	Based on 189,438,135 Common Shares of the Issuer outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024..

Item 1(a)

Name of Issuer:

Arbutus Biopharma Corporation (the “Issuer”)

Item 1(b)

Address of Issuer’s Principal Executive Offices:

701 Veterans Circle

Warminster, PA 18974

Item 2(a)

Name of Person Filing:

The Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)

	i)	Two Seas Capital LP (“TSC”);

	ii)	Two Seas Capital GP LLC (“TSC GP”); and

	iii)	Sina Toussi.

This statement relates to Common Shares (as defined in Item 2(d) below) held by Two Seas Global (Master) Fund LP (the “Global Fund”) and Two Seas LNP Opportunities (Master) Fund LP (the “Opportunities Fund”, and together with the Global Fund, the “Funds”). The principal business of TSC is providing investment advice as a registered investment adviser and serving as investment manager to the Funds and other advisory clients. As such, TSC has been granted investment discretion over portfolio investments, including the Common Shares, held by or for the account of the Funds, including the Funds’ voting and discretionary decisions. TSC GP serves as general partner of TSC. Sina Toussi serves as the Chief Investment Officer of TSC and Managing Member of TSC GP.

Item 2(b)

Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each of the Reporting Persons is 32 Elm Place, 3rd Floor, Rye, New York 10580.

Item 2(c)

Citizenship:

	i)	Two Seas Capital LP is a Delaware limited partnership;

	ii)	Two Seas Capital GP LLC is a Delaware limited liability company; and

	iii)	Sina Toussi is a United States citizen.

Item 2(d)

Title of Class of Securities:

Common Shares, without par value (the “Common Shares”)

Item 2(e)

CUSIP No.:

03879J100

Item 3

If this statement is filed pursuant to §§ 240 13d-1(b), or 240 13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

(b)	☐	Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)	☒	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☒	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);


(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.

Item 4

Ownership:

(a)	Amount beneficially owned:

TSC - 8,387,388 Common Shares

TSC GP - 8,387,388 Common Shares

Sina Toussi - 8,387,388 Common Shares

(b)	Percent of class:

TSC - 4.4%

TSC GP - 4.4%

Sina Toussi - 4.4%

(c)	Number of shares as to which TSC has:

(i) Sole power to vote or to direct the vote: 8,387,388

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 8,387,388

(iv) Shared power to dispose or to direct the disposition of: 0

Number of shares as to which TSC GP has:

(i) Sole power to vote or to direct the vote: 8,387,388

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 8,387,388

(iv) Shared power to dispose or to direct the disposition of: 0

Number of shares as to which Sina Toussi has:

(i) Sole power to vote or to direct the vote: 8,387,388

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 8,387,388

(iv) Shared power to dispose or to direct the disposition of: 0

The Common Shares reported for Item 4 total 8,387,388, of which 5,196,668 are held by the Global Fund and 3,190,720 are held by the Opportunities Fund. TSC may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as investment adviser of the Funds. TSC GP may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as general partner of TSC. Sina Toussi may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through his capacity as Managing Member of TSC GP.

The percentages reported for Item 4(b) are calculated based on a total of 189,438,135 Common Shares outstanding on September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024.

Item 5

Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ☒.

Item 6

Ownership of More Than Five Percent on Behalf of Another Person:

See disclosure in Item 4, which is incorporated by reference herein.

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

See disclosure in Item 2, which is incorporated by reference herein.

Item 8

Identification and Classification of Members of the Group:

This Item 8 is not applicable.

Item 9

Notice of Dissolution of Group:

This Item 9 is not applicable.

Item 10

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.


Dated: November 14, 2024						Two Seas Capital LP

						By Two Seas Capital GP LLC, its General Partner

						By: /s/ Sina Toussi
						Sina Toussi
						Managing Member

Dated: November 14, 2024						Two Seas Capital GP LLC

						By: /s/ Sina Toussi
						Sina Toussi
						Managing Member

Dated: November 14, 2024						Sina Toussi

						By: /s/ Sina Toussi

Kairos Capital Management SC 13G/AArbutus Biopharma / Two Seas Capital ownership change